Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| AMTX | 8-K | bearish | 7/10 | Aemetis reported Q1 2026 revenue of $54.6M, a 27% YoY increase but a 47% miss vs consensus of $103.1M. EPS of -$0.33 mis | May 7, 2026 |
| FOLD | 15-12G | neutral | 4/10 | Amicus Therapeutics filed a Form 15-12G to deregister its securities following its acquisition by BioMarin Pharmaceutica | May 7, 2026 |
| CVKD | PRESS-RELEASE | bullish | 6/10 | Cadrenal Therapeutics reported Q1 2026 EPS of -$1.04, beating the -$1.57 consensus by 33.8%. The company also announced | May 7, 2026 |
| QNRX | PRESS-RELEASE | bullish | 6/10 | Quoin Pharmaceuticals reported Q1 2026 loss per ADS of $(1.77), beating consensus of $(2.26), with no revenue. The compa | May 7, 2026 |
| TBPH | 8-K | mixed | 5/10 | Theravance Biopharma reported Q1 2026 revenue of $17.7M (+15% YoY), slightly above the $17.4M consensus, but GAAP EPS of | May 7, 2026 |
| AIM | PRESS-RELEASE | bullish | 6/10 | AIM ImmunoTech announced positive Phase 2 data for Ampligen in recurrent ovarian cancer, showing a 50% objective respons | May 7, 2026 |
| BNTX | 6-K | neutral | 4/10 | BioNTech announced a new $1.0 billion ADS repurchase program authorized through May 6, 2027, to be funded from existing | May 7, 2026 |
| OGEN | 8-K | neutral | 4/10 | Oragenics signed a non-binding Letter of Intent to license CardioDialysis, an extracorporeal blood purification technolo | May 7, 2026 |
| SLNCF | 8-K | neutral | 4/10 | Silence Therapeutics reported Q1 2026 revenue of $0.4M vs consensus $1.5M, a significant miss reflecting early-stage bio | May 7, 2026 |
| XTLB | 6-K | mixed | 6/10 | Nasdaq Hearing Panel granted XTL Biopharmaceuticals an exception to continue listing on Nasdaq until June 30, 2026, cond | May 7, 2026 |
| ATRA | 8-K | neutral | 4/10 | Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study with an appropriate h | May 7, 2026 |
| PRME | 8-K | bearish | 6/10 | Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.24 by 16.7%, and revenue of $856K, down 41% YoY. | May 7, 2026 |
| FLNA | 8-K | bearish | 7/10 | Filana Therapeutics (FLNA) reported Q1 2026 results with a net loss of $10.3M ($0.21/share), narrower than the $23.4M lo | May 7, 2026 |
| ALXO | PRESS-RELEASE | neutral | 4/10 | ALX Oncology presented exploratory Phase 1b/2 data at ESMO Breast Cancer 2026 showing that evorpacept plus zanidatamab a | May 7, 2026 |
| SLDB | PRESS-RELEASE | bullish | 7/10 | Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, a gene therapy for Duche | May 7, 2026 |
| PRME | PRESS-RELEASE | bearish | 5/10 | Prime Medicine reported Q1 2026 EPS of -$0.28, missing consensus of -$0.25 by 12%, and collaboration revenue of $856K ve | May 7, 2026 |
| SPRY | PRESS-RELEASE | neutral | 1/10 | ARS Pharmaceuticals, Inc. announced it will host a conference call on May 15, 2026 to discuss its Q1 2026 results. | May 7, 2026 |
| FLNA | PRESS-RELEASE | neutral | 4/10 | Filana Therapeutics reported Q1 2026 net loss of $0.21 per share, beating consensus of -$0.23 by 8.7%, driven by reduced | May 7, 2026 |
| PRAX | PRESS-RELEASE | bullish | 8/10 | Praxis Precision Medicines reported Q1 2026 EPS of -$3.20 (GAAP), a 2.7% beat vs consensus of -$3.68, but the headline i | May 7, 2026 |
| MDWD | PRESS-RELEASE | neutral | 1/10 | MediWound Ltd. announced it will report its Q1 2026 results on May 27, 2026. | May 7, 2026 |
| VCEL | 8-K | bullish | 7/10 | Vericel reported Q1 2026 total revenue of $68.4M (+30% YoY), beating the $63.6M consensus, and a GAAP net loss of $0.12/ | May 7, 2026 |
| ASND | 6-K | bullish | 8/10 | Ascendis Pharma reported Q1 2026 revenue of €247M (up 144% YoY from €101M), driven by YORVIPATH sales of €197M. The comp | May 7, 2026 |
| VTRS | 8-K | bullish | 7/10 | Viatris reported Q1 2026 adjusted EPS of $0.59, 18% above consensus of $0.50, and revenue of $3.52B, 5% above consensus | May 7, 2026 |
| ASND | 6-K | bullish | 7/10 | Ascendis Pharma reported Q1 2026 revenue of €246.6M (+144% YoY), driven by YORVIPATH sales tripling to €196.9M. Operatin | May 7, 2026 |
| VCEL | PRESS-RELEASE | bullish | 8/10 | Vericel reported Q1 2026 revenue of $68.4M (+30% YoY) and GAAP EPS of -$0.12 (vs consensus -$0.16, a 25% beat on the los | May 7, 2026 |
| EVAX | 6-K | neutral | 3/10 | Evaxion reported Q1 2026 results with net loss widening to $3.6M from $1.6M due to lower financial income, while operati | May 7, 2026 |
| CRDL | 6-K | bullish | 6/10 | Cardiol Therapeutics announced that its Phase II MAvERIC results for CardiolRx in recurrent pericarditis were accepted f | May 7, 2026 |
| LNTH | 8-K | mixed | 6/10 | Lantheus reported Q1 2026 revenue of $377.3M (beat consensus $354.4M) and adjusted EPS of $1.46 (beat $1.23), but adjust | May 7, 2026 |
| ZURA | 8-K | neutral | 3/10 | Zura Bio reported Q1 2026 net loss of $24.2M ($0.22/share), wider than consensus estimate of -$0.17 and the year-ago los | May 7, 2026 |
| VERA | 8-K | neutral | 4/10 | Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per share, wider than the $0.81 loss in Q1 2025, dri | May 7, 2026 |